🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Determine whether viagenpumatucel-L combined with low-dose cyclophosphamide...
Status
Terminated
Location
Highlands Oncology Group
Start Date
2014-07
Trial ID
NCT02117024
This trial is to further study the safety and effectiveness of autologous g...
Status
Unknown
Location
Multiple Locations
Start Date
2019-12-19
Trial ID
NCT04206254
Treatments Being Tested
RATIONALE: Vaccines made from a person's tumor cells may help the body buil...
Status
Completed
Location
University of Miami Sylvester Comprehensive Cancer Center
Start Date
2007-05
Trial ID
NCT00503568
Treatments Being Tested
Phase I/II study: Phase 1 is an open-label, safety study, patients who prev...
Status
Terminated
Location
University of California at Los Angeles
Start Date
2013-12
Trial ID
NCT02010203
RATIONALE: heat shock protein gp96-peptide complex made from a person's tum...
Status
Completed
Location
Beijing Tiantan Hospital Affiliated to Capital Medical University
Start Date
2013-07
Trial ID
NCT02122822
Treatments Being Tested
Vaccines made from a person's tumor cells, such as gp96 heat shock protein-...
Status
Completed
Location
University of California, San Francisco
Start Date
2005-11-18
Trial ID
NCT00293423
Treatments Being Tested
RATIONALE: Vaccines made from a person's cancer cells may make the body bui...
Status
Completed
Location
Memorial Sloan-Kettering Cancer Center
Start Date
1997-03
Trial ID
NCT00003025
Treatments Being Tested
This study will test whether vaccination with viagenpumatucel-L combined wi...
Status
Completed
Location
University of Arizona Cancer Center
Start Date
2015-04-15
Trial ID
NCT02439450
Treatments Being Tested
To evaluate the safety and effectiveness of autologous gp96 treatment of li...
Status
Unknown
Location
Cancer Insititute and Hospital,Chinese Academy of Medical Sciences
Start Date
2012-03
Trial ID
NCT02133079
Treatments Being Tested
NSCLC tumors are appropriate targets for active immunotherapy, because they...
Status
Withdrawn
Location
Multiple Locations
Start Date
2014-12
Trial ID
NCT01799161
Treatments Being Tested